Pioneers in the development of bacterial spores as heat stable mucosal vaccines. Oral and sub-lingual delivery.
Expertise in Bacillus probiotics. Development and licensing of novel Bacillus carotenoid rich strains.
Development of Bacillus spores for directed targeting of cancerous cells with anti-tumour drugs
Strain constructions, genetic engineering of Bacillus, QPS and GRAS safety assessments, and more
· SPOR-COVTM prophylactic approach targets the innate immune system with potential to develop COVID-19 protection within a few days of treatment
· Innovate UK grant of £800,000 to support SPOR-COV programme over the next 18 months
Read More